ETF Holdings Breakdown of FATE

FATE institutional holdings

The adjusted close for FATE on 2025-11-11 was 1.12

The following institutional investment holdings of FATE have been identified

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share	Comment
2025-11-11	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	69,972	USD 78,369 2.7%	1.12
2025-11-11	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	69,972	USD 78,369 2.7%	1.12
Total =		139,944	USD 156,738

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with FATE

Fate Therapeutics (NASDAQ:FATE) & Cyclerion Therapeutics (NASDAQ:CYCN) Head-To-Head Analysis

Fate Therapeutics (NASDAQ:FATE – Get Free Report) and Cyclerion Therapeutics (NASDAQ:CYCN – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings. Risk & Volatility Fate Therapeutics has a […] - 2025-08-29 02:14:49

Brokerages Set Fate Therapeutics, Inc. (NASDAQ:FATE) Price Target at $3.83

Shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Get Free Report) have been assigned an average rating of “Hold” from the eight ratings firms that are covering the company, Marketbeat reports. Seven equities research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 1 […] - 2025-06-24 02:54:47

Squarepoint Ops LLC Purchases 20,805 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE)

Squarepoint Ops LLC grew its position in shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) by 154.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 34,295 shares of the biopharmaceutical company’s stock after acquiring an additional 20,805 […] - 2025-06-11 05:08:50

Bank of America Corp DE Reduces Position in Fate Therapeutics, Inc. (NASDAQ:FATE)

Bank of America Corp DE lessened its holdings in shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) by 64.4% in the 4th quarter, Holdings Channel reports. The institutional investor owned 304,129 shares of the biopharmaceutical company’s stock after selling 550,066 shares during the quarter. Bank of America Corp DE’s holdings in Fate Therapeutics were […] - 2025-06-11 04:14:58

Graham Capital Management L.P. Buys New Shares in Fate Therapeutics, Inc. (NASDAQ:FATE)

Graham Capital Management L.P. bought a new stake in shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 22,342 shares of the biopharmaceutical company’s stock, valued at approximately $37,000. Other large investors […] - 2025-05-20 05:40:49

D. E. Shaw & Co. Inc. Decreases Position in Fate Therapeutics, Inc. (NASDAQ:FATE)

D. E. Shaw & Co. Inc. lessened its holdings in shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) by 54.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,536,633 shares of the biopharmaceutical company’s stock after selling 1,841,017 shares […] - 2025-05-20 04:56:58

Hsbc Holdings PLC Has $179,000 Stock Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE)

Hsbc Holdings PLC grew its stake in Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) by 22.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 109,422 shares of the biopharmaceutical company’s stock after purchasing an additional 19,706 shares during the quarter. Hsbc […] - 2025-05-12 04:56:49

Fate Therapeutics, Inc. (NASDAQ:FATE) Receives $5.43 Consensus PT from Analysts

Shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Get Free Report) have been given a consensus rating of “Hold” by the nine research firms that are presently covering the firm, Marketbeat reports. Seven equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average […] - 2025-05-05 03:13:09

CANADA LIFE ASSURANCE Co Has $35,000 Stock Position in Fate Therapeutics, Inc. (NASDAQ:FATE)

CANADA LIFE ASSURANCE Co trimmed its position in Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) by 53.4% in the fourth quarter, Holdings Channel.com reports. The firm owned 21,267 shares of the biopharmaceutical company’s stock after selling 24,365 shares during the period. CANADA LIFE ASSURANCE Co’s holdings in Fate Therapeutics were worth $35,000 at the end […] - 2025-05-01 05:50:46

Marshall Wace LLP Makes New Investment in Fate Therapeutics, Inc. (NASDAQ:FATE)

Marshall Wace LLP bought a new position in shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 512,641 shares of the biopharmaceutical company’s stock, valued at approximately $846,000. Marshall Wace LLP owned approximately 0.45% of Fate […] - 2025-05-01 04:53:01

Cerity Partners LLC Grows Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE)

Cerity Partners LLC boosted its holdings in shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) by 4,953.6% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 823,134 shares of the biopharmaceutical company’s stock after purchasing an additional 806,846 shares during the period. Cerity Partners LLC owned […] - 2025-04-18 05:06:56

Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Sold by Prudential Financial Inc.

Prudential Financial Inc. trimmed its position in shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) by 9.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 321,401 shares of the biopharmaceutical company’s stock after selling 35,200 shares during the […] - 2025-04-09 04:51:00

Fate Therapeutics (NASDAQ:FATE) Lowered to “Sell” Rating by StockNews.com

StockNews.com cut shares of Fate Therapeutics (NASDAQ:FATE – Free Report) from a hold rating to a sell rating in a research note issued to investors on Tuesday. FATE has been the topic of a number of other reports. Stifel Nicolaus cut their target price on Fate Therapeutics from $5.00 to $3.00 and set a “hold” […] - 2025-03-12 04:42:57

Fate Therapeutics (NASDAQ:FATE) Upgraded by StockNews.com to Hold Rating

Fate Therapeutics (NASDAQ:FATE – Get Free Report) was upgraded by investment analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Monday. A number of other research firms have also issued reports on FATE. Wedbush reaffirmed a “neutral” rating and set a $5.00 target price on […] - 2025-03-05 04:52:57

Back to Listing

Disclaimer